大麻坦 | 66556-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 大麻坦
• 中文别名: 钠比宁
• 英文名称: 4-piperidin-1-yl-butyric acid 8-(1,2-dimethyl-heptyl)-5,5-dimethyl-2-prop-2-ynyl-1,3,4,5-tetrahydro-2H-chromeno[4,3-c]pyridin-10-yl ester
• 英文别名: 5,5-dimethyl-10-[4-(piperidino)butyryloxy]-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano [3,4-d]pyridine；nabitan；[5,5-dimethyl-8-(3-methyloctan-2-yl)-2-prop-2-ynyl-3,4-dihydro-1H-chromeno[4,3-c]pyridin-10-yl] 4-piperidin-1-ylbutanoate
• CAS: 66556-74-9
• 化学式: C₃₅H₅₂N₂O₃
• 分子量: 548.809
• InChiKey: MCVPMHDADNVRKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  40
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• PREPARATION AND UTILITY OF SUBSTITUTED PYRAZOLE COMPOUNDS WITH CANNABINOID RECEPTOR ACTIVITY
  申请人：GANT G. Thomas

  公开号：US20070287734A1

  公开（公告）日：2007-12-13

  The present disclosure is directed to modulators of CB-1 type receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of obesity, metabolic syndrome, dyslipidemia, glucose imbalance, the inability to maintain weight loss, insulin resistance, a cardiovascular disorder, memory loss, drug dependence, a depressive disorder, a panic disorder, an obsessive-compulsive disorder, anxiety, post-traumatic stress syndrome, and any other condition in which it is beneficial to inhibit, inversely agonize or modulate a cannabinoid receptor are described.

  本披露涉及CB-1型受体的调节剂及其药用盐和前药，其化学合成，以及这些化合物的医学用途，用于治疗和/或管理肥胖、代谢综合征、血脂异常、葡萄糖失衡、无法维持体重减轻、胰岛素抵抗、心血管疾病、记忆丧失、药物依赖、抑郁症、恐慌症、强迫症、焦虑、创伤后应激综合征以及其他有益于抑制、反向激动或调节大麻素受体的情况。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS
  申请人：Kindler Seth

  公开号：US20110195096A1

  公开（公告）日：2011-08-11

  Compositions which include a corticosteroid in combination with an additional compound active in treatment of an inflammatory disorder are provided.

  本发明提供了一种包括皮质类固醇与另一种在治疗炎症性疾病方面具有活性的化合物的组合物。